2. Search Result
Search Result
Isoforms Recommended: Aurora B
Results for "

Aurora-B

" in MedChemExpress (MCE) Product Catalog:

48

Inhibitors & Agonists

2

Natural
Products

1

Isotope-Labeled Compounds

1

Antibodies

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112355
    Aurora kinase inhibitor-2

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .
    Aurora kinase inhibitor-2
  • HY-10329
    JNJ-7706621
    2 Publications Verification

    		 Aurora Kinase CDK Apoptosis Cancer
    JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively .
    JNJ-7706621
  • HY-18161
    CCT241736

    		FLT3 Aurora Kinase Cancer
    CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM).
    CCT241736
  • HY-124526
    Chiauranib

    Ibcasertib; CS2164

    		 VEGFR PDGFR c-Kit Aurora Kinase c-Fms Cancer
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .
    Chiauranib
  • HY-141512
    JB170
    1 Publications Verification

    		 PROTACs Aurora Kinase Cancer
    JB170 is a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM) by linking Alisertib, to the Cereblon-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC50=193 nM) over AURORA-B (EC50=1.4 µM). JB170-mediated S-phase arrest is caused specifically by AURORA-A depletion. JB170 has excellent ability to inhibit non-catalytic function of AURORA-A kinase .
    JB170
  • HY-10558
    CYC-116
    3 Publications Verification

    		 Aurora Kinase Cancer
    CYC-116 is a potent aurora A and aurora B inhibitor with Kis of 8 and 9 nM, respectively.
    CYC-116
  • HY-U00304
    Aurora B inhibitor 1

    		Aurora Kinase Cancer
    Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
    Aurora B inhibitor 1
  • HY-N3634
    Corylifol C

    		EGFR TAM Receptor Tie Cancer
    Corylifol C is a potent protein kinase inhibitor with IC50 valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .
    Corylifol C
  • HY-121998
    Binucleine 2

    		Aurora Kinase Others
    Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.
    Binucleine 2
  • HY-12054A
    Hesperadin hydrochloride

    		Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC50 of 250 nM .
    Hesperadin hydrochloride
  • HY-111506
    Aurora inhibitor 1

    		Aurora Kinase Cancer
    Aurora inhibitor 1 is a potent Aurora inhibitor with an IC50 of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively .
    Aurora inhibitor 1
  • HY-125158A
    (E/Z)-HOI-07

    		Aurora Kinase Cancer
    (E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity .
    (E/Z)-HOI-07
  • HY-14711
    Reversine
    10+ Cited Publications

    		 Aurora Kinase Autophagy Cancer
    Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC50s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.
    Reversine
  • HY-14574
    PF-03814735
    2 Publications Verification

    		 Aurora Kinase VEGFR Cancer
    PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and aurora B inhibitor with IC50s of 0.8 and 0.5 nM, respectively.
    PF-03814735
  • HY-124330
    Tripolin A

    (E)-Tripolin A

    		 Aurora Kinase Others
    Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive Aurora A kinase inhibitor, with IC50 values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively .
    Tripolin A
  • HY-70044
    GSK-1070916
    5 Publications Verification

    GSK-1070916A

    		 Aurora Kinase Apoptosis Cancer
    GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
    GSK-1070916
  • HY-N3737
    Derrone

    		Aurora Kinase PERK Reactive Oxygen Species Cancer
    Derrone, a prenylated isoflavones, is an Aurora kinase inhibitor, with IC50 values of 6 and 22.3 μM against Aurora B and Aurora A, respectively. Derrone shows anti-tumor activity .
    Derrone
  • HY-147993
    Aurora kinase inhibitor-10

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC50 of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .
    Aurora kinase inhibitor-10
  • HY-10126
    Barasertib-HQPA
    5+ Cited Publications

    AZD2811; INH-34; AZD1152-HQPA

    		 Aurora Kinase Apoptosis Cancer
    Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells .
    Barasertib-HQPA
  • HY-122370A
    Tripolin B

    		Aurora Kinase Cancer
    Tripolin B is an ATP-competitive Aurora kinase inhibitor with IC50 values of 2.5 µM and 6 µM for Aurora A and Aurora B kinases, respectively. Tripolin B does not inhibit Aurora kinase in cells .
    Tripolin B
  • HY-10127A
    Barasertib dihydrochloride

    AZD1152 dihydrochloride

    		 Aurora Kinase Apoptosis Cancer
    Barasertib (AZD1152 dihydrochloride), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152 dihydrochloride) induces growth arrest and apoptosis in cancer cells .
    Barasertib dihydrochloride
  • HY-10127
    Barasertib
    Maximum Cited Publications
    18 Publications Verification

    AZD1152

    		 Aurora Kinase Apoptosis Cancer
    Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells .
    Barasertib
  • HY-12054
    Hesperadin
    5+ Cited Publications

    		 Aurora Kinase Autophagy Influenza Virus Parasite Cancer
    Hesperadin is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin inhibits Aurora B with an IC50 of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis. Hesperadin also is a broad-spectrum influenza antiviral .
    Hesperadin
  • HY-W140760
    Ceftriaxone sodium

    		Antibiotic Infection Inflammation/Immunology Cancer
    Ceftriaxone sodium is a versatile broad-spectrum β-lactam tertiary cephalosporin antibiotic that exhibits anti-inflammatory, antitumor, antibacterial, and antioxidant properties, and functions as a covalent inhibitor of GSK3β and Aurora B, making it valuable in research related to sepsis and infective endocarditis.
    Ceftriaxone sodium
  • HY-12476
    SAR156497

    		Phosphodiesterase (PDE) Aurora Kinase Cancer
    SAR156497 (compound 47) is an Aurora inhibitor, with IC50 values ​​of 0.6 nM and 1 nM for Aurora A and Aurora B, respectively. SAR156497 can also inhibit PDE3, with IC50 value of 4 μM. SAR156497 can be used in anticancer research .
    SAR156497
  • HY-103266
    TC-A 2317 hydrochloride

    		Aurora Kinase Cancer
    TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .
    TC-A 2317 hydrochloride
  • HY-137377
    TAS-119

    		Aurora Kinase Cancer
    TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC50 of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC50 of 95 nM). TAS-119 has potent antitumor activites .
    TAS-119
  • HY-147703
    Aurora kinase inhibitor-9

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC50s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .
    Aurora kinase inhibitor-9
  • HY-10057
    AT9283 hydrochloride

    		Aurora Kinase Cancer
    AT9283 hydrochloride is a multi-targeted kinase inhibitor with anti-tumor activity. AT9283 hydrochloride has been found to effectively inhibit Aurora A and Aurora B kinases, thereby affecting cell proliferation and survival. AT9283 hydrochloride can also inhibit several other kinases, including JAK2 and Abl (T315I) .
    AT9283 hydrochloride
  • HY-16018A
    Ilorasertib hydrochloride

    ABT-348 hydrochloride

    		 Aurora Kinase PDGFR VEGFR Cancer
    Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
    Ilorasertib hydrochloride
  • HY-16018
    Ilorasertib

    ABT-348

    		 Aurora Kinase VEGFR PDGFR Cancer
    Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .
    Ilorasertib
  • HY-150592
    Aurora kinase-IN-2

    		Aurora Kinase Cancer
    Aurora kinase-IN-2 (compound 12Aj) is a potent Aurora kinase inhibitor with IC50 values of 90 and 152 nM for Aurora A and Aurora B. Aurora kinase-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora kinase-IN-2 can be used for cancer research .
    Aurora kinase-IN-2
  • HY-125158
    HOI-07

    		Aurora Kinase Apoptosis Cancer
    HOI-07 is a selective Aurora B kinase inhibitor. HOI-07 blocks phosphorylation of histone H3 on Ser10 in lung cancer cells. HOI-07 induces cell-cycle arrest, and apoptosis. HOI-07 has antitumor activity, and suppresses the tumor growth of A549, 143B and KHOS xenografts .
    HOI-07
  • HY-107419
    NU6140
    1 Publications Verification

    		 CDK Aurora Kinase Cancer
    NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs . NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively . Enhances the apoptotic effect, with anti-cancer activity .
    NU6140
  • HY-123279
    OM137

    		Aurora Kinase CDK Cancer
    OM137 is an aurora kinase inhibitor, with an IC50 of 21.7 μM (Aurora A kinase) and 2.4 μM (Aurora B kinase). OM137 also inhibits Cdk1/cyclinB and Cdk5/p25 with an approximate IC50 of 20 μM. OM137 reduces spindle checkpoint-signaling proteins (Mad2 and BubR1) at the kinetochores of chromosomes .
    OM137
  • HY-132135
    (1E)-CFI-400437 dihydrochloride

    		Polo-like Kinase (PLK) Cancer
    (1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC50s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .
    (1E)-CFI-400437 dihydrochloride
  • HY-144075
    JAK-IN-19

    		JAK Inflammation/Immunology
    JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC50=7.0, Aurora B pIC50=5.8) .
    JAK-IN-19
  • HY-131339
    SP-96
    1 Publications Verification

    		 Aurora Kinase Cancer
    SP-96 is a?highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI50=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .
    SP-96
  • HY-112809
    GSK2646264

    		Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase Inflammation/Immunology
    GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .
    GSK2646264
  • HY-B0712A
    Ceftriaxone sodium hydrate
    5+ Cited Publications

    Ro 13-9904 sodium hydrate

    		 Bacterial Antibiotic GSK-3 Aurora Kinase Infection Cancer
    Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .
    Ceftriaxone sodium hydrate
  • HY-B0712
    Ceftriaxone
    5+ Cited Publications

    Ro 13-9904 free acid

    		 Bacterial Antibiotic GSK-3 Aurora Kinase Infection Inflammation/Immunology Cancer
    Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
    Ceftriaxone
  • HY-B0712B
    Ceftriaxone sodium salt
    5+ Cited Publications

    Ro 13-9904

    		 Antibiotic GSK-3 Bacterial Aurora Kinase Infection Inflammation/Immunology Cancer
    Ceftriaxone sodium salt (Ro 13-9904) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium salt is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium salt is an inhibitor of Aurora B. Ceftriaxone sodium salt has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium salt can be used in the study of bacterial infections and meningitis .
    Ceftriaxone sodium salt
  • HY-116423A
    JH295 hydrate

    		NEKs Cancer
    JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    JH295 hydrate
  • HY-15196
    TAK-285
    2 Publications Verification

    		 EGFR Cancer
    TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .
    TAK-285
  • HY-116423
    JH295

    		NEKs Cancer
    JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    JH295
  • HY-B0712AR
    Ceftriaxone (sodium hydrate) (Standard)

    		Bacterial Antibiotic GSK-3 Aurora Kinase Infection Cancer
    Ceftriaxone (sodium hydrate) (Standard) is the analytical standard of Ceftriaxone (sodium hydrate). This product is intended for research and analytical applications. Ceftriaxone sodium hydrate (Ro 13-9904 sodium hydrate) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone sodium hydrate is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone sodium hydrate is an inhibitor of Aurora B. Ceftriaxone sodium hydrate has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone sodium hydrate can be used in the study of bacterial infections and meningitis .
    Ceftriaxone (sodium hydrate) (Standard)
  • HY-168718
    FAK-IN-22

    		FAK JAK Aurora Kinase PI3K Akt Apoptosis Cancer
    FAK-IN-22 (Compound 26) is an inhibitor of FAK, JAK3, and Aurora B, with IC50 values of 50.94 nM, 9.99 nM, and 0.49 nM, respectively, effectively inhibiting tumor occurrence and metastasis in pancreatic ductal adenocarcinoma (PDAC). FAK-IN-22 effectively inhibits the proliferation of PANC-1 cells, with an IC50 value of 0.15 μM. FAK-IN-22 induces apoptosis and G2/M phase arrest in PANC-1 cells by inhibiting the FAK/PI3K/Akt signaling pathway .
    FAK-IN-22
  • HY-B0712S1
    Ceftriaxone-13C2,d3 triethylammonium salt

    Ro 13-9904-13C2,d3 triethylammonium salt

    		 Antibiotic Aurora Kinase GSK-3 Bacterial Isotope-Labeled Compounds Infection Inflammation/Immunology Cancer
    Ceftriaxone- 13C2,d3 triethylammonium salt is 13C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .
    Ceftriaxone-13C2,d3 triethylammonium salt

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: